Allecra kicks off with €15m
Enlarge image


Allecra kicks off with €15m

19.04.2013 - Edmond de Rothschild and Forbion Capital Partners have co-led a Series A investment in anti-infectives company, Allecra Therapeutics.

Antibiotic resistance is a global problem, which has triggered huge investments into  development of new drugs against difficult to treat bugs. Yesterday,  Allecra Therapeutics GmbH started operations with a co-investment totalling €15m from Edmond de Rothschild Investment Partners, Forbion Capital Partners and EMBL Venture Funds. The German-French company (Loerrach, Saint Louis) aims to bring two novel antibiotics to clinical stage targeting multi-drug resistant gram-negative bugs such as Pseudomonas aeruginosa or Klebsiella pneumoniae. IP has been already in-licenced from Indian Orchid Chemicals & Therapeutics Ltd in Chennai.   

According to Orchid Chairman Raghavendra Rao, his company received a €1m upfront payment. „This is a big shot in arm for our drug discovery programme because we have been investing in basic R&D for some time now. We will be holding around 20% shareholding into that company and molecule and, as it progresses, we will get further revenues from it in the form of exit bonuses and further royalties.“ The Indian company recently reported progress in the antibiotic field boosting the performance of common antibiotics by application of silver nanoparticles provided by the fungus Trichoderma viridus. 

Allecra’s drug development will be based on a strategic partnership between Allecra’s founders headed by CEO Nicolas Benedict with Orchid. Allecra’s Board member Holger Reithinger from Forbion Capital said: “We have a specialist team, each of whom is deeply experienced in the development of antibiotics and which collectively is supported by a world-leading group of Opinion Leaders.” Board member Olivier Litzka from Edmond de Rothschild Investment Partners added: “Allecra’s strategic partnership with Orchid is an innovative collaboration bringing together Allecra’s strong development capability with Orchid’s track record in antibiotic research and manufacturing. This is a new company built on a solid foundation for success.”



07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


17.09.2015 Another European biotech is coming with a hefty price tag for its US buyer. Amgen Inc. has acquired privatly held Dutch company Dezima Pharma B.V. for US$1.55bn (€1.37bn).


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • PHARMING (NL)0.31 EUR19.23%


  • THERAMETRICS (CH)0.04 CHF-33.33%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.13 EUR48.6%
  • OREXO (S)66.00 SEK36.9%
  • ZEALAND PHARMA (DK)156.00 DKK22.4%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • TIGENIX (B)0.88 EUR-27.9%


  • KARO BIO (S)43.60 SEK5282.7%
  • CHRONTECH PHARMA (S)0.35 SEK337.5%
  • GALAPAGOS (B)38.43 EUR225.7%


  • NEOVACS (F)0.70 EUR-77.8%
  • BIOTEST (D)19.15 EUR-74.6%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 08.10.2015